摘要
目的观察中大剂量阿糖胞苷(HD/IDAra-C)在急性髓性白血病(AML)缓解后的巩固强化治疗的疗效。方法将诱导缓解后的32例AML患者分为对照组和治疗组,比较含中大剂量阿糖胞苷方案与标准的巩固强化治疗方案对两组患者治疗后3年和5年无病生存率(DFS)和总生存期(OS)以及治疗后复发率的影响。结果对照组3年和5年DFS分别为19.2%和0%,中位生存期10.8个月,巩固后早期复发率76.1%;治疗组3年和5年DFS分别为51.4%和25.1%,中位生存期28.6个月,巩固后早期复发率44.7%。两组间差别均有显著性意义(P<0.05)。结论HD/IDAra-C能克服耐药,延长患者无病生存率和总生存期,降低复发率,对AML缓解后的巩固强化治疗疗效好。
OBJECTIVE To investigate the effect of postremission consolidation therapy with intermedium to high -dose cytarabine（ HD/ID Ara -C） in acute myelogenous leukemia（AML） . METHODS 32 cases with AML in postremission were randomly divided into treatment group（ 19 Cases） and control group （ 13 cases）. Patients in treatment group were carried HD/ID Ara - C while, patients in control group were only carried routine chemical therapy. The disease -free survival（DFS） at three years and five years, overall survival （OS） and the recurrent rates between two groups were compared. RESULTS After consolidation therapy, the expectation of DFS at three years and five years in control group was 19.2% and 0% , the median OS was 10.8 months and the recurrent rates was 76. 1%. While in treatment group, the DFS at three years and five years was 51.4% and 25.1% , respectively, the median OS was 28.6 months and the recurrent rates was 44.7%. The differences between two groups were significant （P 〈0.05）. CONCLUSION The postremission consolidation chemotherapy with HD/ID Ara- C can overcome the drug resistance , prolong DFS and OS , and decrease the recurrent rate. It is a good way of postremission consolidation therapy in AML.
出处
《海峡药学》
2007年第12期77-78,84,共3页
Strait Pharmaceutical Journal
关键词
中大剂量阿糖胞苷
急性髓性白血病
巩固强化治疗
Intermediate/high- dose cytarabine
Acute myeloid leukemia
Consolidation chemotherapy
